Losmapimod

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Losmapimod
DrugBank Accession Number
DB12270
Background

Losmapimod has been investigated for the prevention of Chronic Obstructive Pulmonary Disease.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 383.467
Monoisotopic: 383.200905252
Chemical Formula
C22H26FN3O2
Synonyms
  • Losmapimod
External IDs
  • GW-856553X
  • GW856553
  • GW856553X

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Phenylpyridines
Direct Parent
Phenylpyridines
Alternative Parents
3-halobenzoic acids and derivatives / p-Toluamides / Benzamides / Nicotinamides / Benzoyl derivatives / Fluorobenzenes / Aryl fluorides / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds
show 6 more
Substituents
2-phenylpyridine / 3-halobenzoic acid or derivatives / Aromatic heteromonocyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzamide / Benzenoid / Benzoic acid or derivatives / Benzoyl
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
F2DQF16BXE
CAS number
585543-15-3
InChI Key
KKYABQBFGDZVNQ-UHFFFAOYSA-N
InChI
InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28)
IUPAC Name
6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide
SMILES
CC1=C(C=C(C=C1F)C(=O)NC1CC1)C1=CC=C(C=N1)C(=O)NCC(C)(C)C

References

General References
Not Available
PubChem Compound
11552706
PubChem Substance
347828541
ChemSpider
9727484
BindingDB
50418610
ChEBI
131167
ChEMBL
CHEMBL1088752
ZINC
ZINC000035793138
Wikipedia
Losmapimod

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
3CompletedTreatmentAcute Coronary Syndrome (ACS)1
2Active Not RecruitingTreatmentFacioscapulohumeral Muscular Dystrophy 11
2CompletedPreventionChronic Obstructive Pulmonary Disease (COPD)1
2CompletedTreatmentAcute Coronary Syndrome (ACS)1
2CompletedTreatmentAtherosclerosis1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)4
2CompletedTreatmentDyslipidemia / Healthy Volunteers1
2CompletedTreatmentFacioscapulohumeral Muscular Dystrophy (FSHD)1
2CompletedTreatmentGlomerulosclerosis, Focal Segmental1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00393 mg/mLALOGPS
logP3.5ALOGPS
logP3.68ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)13.86ChemAxon
pKa (Strongest Basic)2.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area71.09 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity107.23 m3·mol-1ChemAxon
Polarizability42.79 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 21:47 / Updated on February 21, 2021 18:53